- Home
- ODD vs AZTA Comparison
ODD vs AZTA Comparison
Compare ODD & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- AZTA
- Stock Information
- Founded
- ODD 2018
- AZTA 1978
- Country
- ODD Israel
- AZTA United States
- Employees
- ODD N/A
- AZTA N/A
- Industry
- ODD
- AZTA Industrial Machinery/Components
- Sector
- ODD
- AZTA Technology
- Exchange
- ODD Nasdaq
- AZTA Nasdaq
- Market Cap
- ODD 2.3B
- AZTA 1.8B
- IPO Year
- ODD 2023
- AZTA 1995
- Fundamental
- Price
- ODD $67.74
- AZTA $27.71
- Analyst Decision
- ODD Buy
- AZTA Buy
- Analyst Count
- ODD 8
- AZTA 3
- Target Price
- ODD $54.63
- AZTA $50.67
- AVG Volume (30 Days)
- ODD 1.1M
- AZTA 896.2K
- Earning Date
- ODD 04-29-2025
- AZTA 05-07-2025
- Dividend Yield
- ODD N/A
- AZTA N/A
- EPS Growth
- ODD 45.36
- AZTA N/A
- EPS
- ODD 1.74
- AZTA N/A
- Revenue
- ODD $703,488,000.00
- AZTA $669,171,000.00
- Revenue This Year
- ODD $22.39
- AZTA N/A
- Revenue Next Year
- ODD $20.09
- AZTA $5.38
- P/E Ratio
- ODD $38.12
- AZTA N/A
- Revenue Growth
- ODD 26.83
- AZTA 4.70
- 52 Week Low
- ODD $32.71
- AZTA $24.06
- 52 Week High
- ODD $69.96
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- ODD 82.59
- AZTA 46.72
- Support Level
- ODD $39.55
- AZTA $23.91
- Resistance Level
- ODD $43.14
- AZTA $27.06
- Average True Range (ATR)
- ODD 3.74
- AZTA 1.38
- MACD
- ODD 2.42
- AZTA 0.56
- Stochastic Oscillator
- ODD 92.70
- AZTA 90.69
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.